

Kerry L Burnstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5913459/publications.pdf>

Version: 2024-02-01

23
papers

786
citations

567281

15
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1459
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 657-669.	2.6	106
2	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
3	The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e52106.	2.5	78
4	Vav3, a Rho GTPase Guanine Nucleotide Exchange Factor, Increases during Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity. <i>Molecular Endocrinology</i> , 2006, 20, 1061-1072.	3.7	58
5	Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival. <i>Molecular Endocrinology</i> , 2012, 26, 1967-1979.	3.7	49
6	Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer. <i>Molecular Endocrinology</i> , 2008, 22, 597-608.	3.7	46
7	Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1084-1089.	7.1	40
8	Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. <i>Nature Communications</i> , 2017, 8, 1204.	12.8	40
9	Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11298-11303.	7.1	38
10	Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	36
11	Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. <i>Molecular Systems Biology</i> , 2018, 14, e8202.	7.2	33
12	VAV3 mediates resistance to breast cancer endocrine therapy. <i>Breast Cancer Research</i> , 2014, 16, R53.	5.0	28
13	Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 394-404.	4.1	25
14	Targeting AR Variantâ€™Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. <i>Molecular Cancer Research</i> , 2017, 15, 1469-1480.	3.4	21
15	Novel Interaction between the Co-chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth*. <i>Journal of Biological Chemistry</i> , 2013, 288, 5463-5474.	3.4	20
16	Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. <i>Oncogene</i> , 2019, 38, 838-851.	5.9	19
17	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1353-1363.	4.1	15
18	Essential Components of Cancer Education. <i>Cancer Research</i> , 2015, 75, 5202-5205.	0.9	10

#	ARTICLE	IF	CITATIONS
19	The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. <i>Oncogene</i> , 2022, 41, 2824-2832.	5.9	10
20	A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 9007-9021.	1.8	6
21	Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans. <i>Molecular Cancer Research</i> , 2022, 20, 1295-1304.	3.4	3
22	Signaling Mechanisms of Vav3, a Guanine Nucleotide Exchange Factor and Androgen Receptor Coactivator, in Physiology and Prostate Cancer Progression. , 2013, , 187-205.		0
23	Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 221-221.	1.6	0